Breast Cancer


From the Journals

Use of topical agents before RT may be safe

Using preclinical models, investigators found that when common topical agents were applied at a thickness of less than 2 mm, negligible effects on...

Conference Coverage

SOLAR-1 shines light on PI3K in breast cancer

MUNICH – The selective PI3K inhibitor added to fulvestrant extended progression-free survival in breast cancer patients with PIK3CA mutations.